

Proteome-wide association studies using summary pQTL data of three tissues identified 30 risk genes of Alzheimer's disease dementia

Tingyang Hu^{1,2+}, Qiang Liu^{1,3+}, Qile Dai^{1,3}, Randy L. Parrish^{1,3}, Aron S. Buchman⁴, Shinya Tasaki⁴, Nicholas T. Seyfried⁵, Yanling Wang⁴, David A. Bennett⁴, Philip L. De Jager⁶, Michael P. Epstein¹, Jingjing Yang^{1,*}

Author affiliations:

1. Center for Computational and Quantitative Genetics, Department of Human Genetics, Emory University School of Medicine, Atlanta, GA, 30322, USA
2. Division of Biostatistics and Bioinformatics, Department of Public Health Sciences, Pennsylvania State University College of Medicine, Hershey, PA, 17033, USA
3. Department of Biostatistics and Bioinformatics, Emory University School of Public Health, Atlanta, GA, 30322, USA
4. Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, 60612, USA
5. Department of Biochemistry, Emory University School of Medicine, Atlanta, GA, 30322, USA
6. Center for Translational and Computational Neuroimmunology, Department of Neurology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, New York, NY10032, USA

+. Co-first authors.

*. Correspondence to: Jingjing Yang

Center for Computational and Quantitative Genetics, Department of Human Genetics, Emory University School of Medicine, Atlanta, GA, 30322, USA

jingjing.yang@emory.edu

Abstract

Background: Proteome-wide association study (PWAS) integrating proteomic data with genome-wide association study (GWAS) summary data is a powerful tool for studying Alzheimer's disease (AD) dementia. Existing PWAS analyses of AD often rely on the availability of individual-level proteomic and genetic data of a reference panel. Leveraging summary protein quantitative trait loci (pQTL) reference data of multiple AD-relevant tissues is expected to improve PWAS findings of AD dementia.

Methods: We conducted PWAS of AD dementia by integrating publicly available summary pQTL data of brain, cerebrospinal fluid (CSF), and plasma tissues, with the latest GWAS summary data of AD dementia. For each target protein per tissue, we employed our recently published OTTERS tool to obtain omnibus PWAS p-value, to test whether the genetically regulated protein abundance in the corresponding tissue is associated with AD dementia. Protein-protein interactions and enriched pathways of identified significant PWAS risk genes were analyzed by STRING. The potential causal effects of these PWAS risk genes were assessed by probabilistic Mendelian randomization analyses.

Results: We identified 30 unique significant PWAS risk genes for AD dementia, including 11 for brain, 9 for CSF, and 16 for plasma tissues. Four of these were shared by at least two tissues, and gene *MAPK3* was found in all three tissues. We found that 11 of these PWAS risk genes were associated with AD or AD pathological hall marks as shown in GWAS Catalog; 18 of these were detected by transcriptome-wide association studies (TWAS); and 25 of these, including 8 out of 9 novel genes, were interconnected within a protein-protein interaction network involving the well-known AD risk gene *APOE*. Especially, these PWAS risk genes were enriched in immune response, glial cell proliferation, and high-density lipoprotein particle clearance pathways. Mediated causal effects were validated for 13 PWAS risk genes (43.3%).

Conclusions: Our findings provide novel insights into the genetic mechanisms of AD dementia in brain, CSF, and plasma tissues, and targets for developing therapeutic interventions. We also demonstrated the effectiveness of integrating summary pQTL and GWAS data for mapping risk genes of complex human diseases.

Keywords: PWAS; pQTL; GWAS; Alzheimer's disease; AD dementia; OTTERS.

Background

Large-scale genome-wide association studies (GWAS) have successfully identified dozens of genetic risk loci related to Alzheimer's disease (AD) dementia¹⁻³. However, the underlying molecular mechanisms of these GWAS risk genes of AD are still largely unknown. To gain biological insights into how associated risk genes might contribute to AD dementia, researchers have performed proteome-wide association studies (PWAS) that integrates reference proteomic data from an AD-related tissue with GWAS summary data of AD dementia to identify risk genes whose effects are mediated via genetically regulated protein abundance^{4,5}.

PWAS typically employs a two-stage framework: Stage I uses the genetic and proteomic data of the same reference cohort to train a protein abundance prediction model for each target protein, taking the protein abundance quantitative trait as the response variable and the cis-genetic variants proximal to the protein-coding gene as predictors. The estimated genetic coefficients from Stage I can be viewed as effect sizes of “protein quantitative trait loci (pQTL)” in a broad sense, as most genetic variants with non-zero effect sizes will not be statistically significant pQTL. Stage II proceeds by using the estimated pQTL effect sizes as variant weights to predict genetically regulated protein abundance in a GWAS cohort, and subsequently conducts a gene-based association test (of the corresponding protein-coding gene) relating the predicted abundance of the target protein to phenotype.

Existing analytic tools derived for the analogous transcriptome-wide association studies (TWAS) have been used for PWAS. Existing tools such as TIGAR⁶, PrediXcan⁷, and FUSION⁸, utilize different statistical methods in Stage I to estimate the pQTL weights, requiring individual-level genetic and proteomic data of the reference cohort. For example, by PWAS analyses of AD dementia with the individual-level reference proteomic data of dorsolateral prefrontal cortex (DLPFC) tissue and whole genome sequencing (WGS) genotype data from samples in the Religious Orders Study and Rush Memory and Aging Project (ROS/MAP)⁹, Wingo et al.⁴ detected 11 risk genes by using the FUSION⁸ tool alone and Hu et al.¹⁰ identified 43 risk genes by aggregating results obtained from three tools of TIGAR⁶, PrediXcan⁷, and FUSION⁸.

In this work, we utilized our newly developed OTTERS¹¹ tool to extend the PWAS analyses of AD dementia, by leveraging the summary pQTL data that was recently released and publicly available. This data includes not only brain (parietal lobe cortex, n=380) but also cerebrospinal fluid (CSF, n=835) and plasma (n=529) tissues¹². Recent studies have shown that

amyloid beta ($A\beta$)1-42/ $A\beta$ 1-40 and phosphorylated tau/ $A\beta$ 1-42 ratios in CSF^{13,14} and plasma^{15,16} could be used as biomarkers for early diagnosis of AD. Both CSF and plasma tissues are AD-relevant and important for studying genetic mechanisms of AD dementia. Thus, conducting PWAS with the recent GWAS summary data of AD dementia ($n \sim 789K$)³ in all three tissues (brain, CSF, and plasma) is expected to identify additional risk genes of AD whose genetic effects are potentially mediated through the genetically regulated protein abundances.

Methods

OTTERS framework

In a two-stage PWAS framework with individual-level genetic and proteomic data from a reference panel, Stage I involves fitting a multiple linear regression model (*Equation 1*) with protein abundance (\mathbf{E}_p) of a protein p as the outcome, genotype data (\mathbf{X}) of cis- genetic variants of the corresponding protein-coding gene (i.e., genetic variants located within the $\pm 1\text{Mb}$ region around gene transcription start/termination sites) as predictors, and \mathbf{w} denoting the pQTL weights to be estimated:

$$\mathbf{E}_p = \mathbf{X}\mathbf{w} + \boldsymbol{\epsilon}; \quad \boldsymbol{\epsilon} \sim N(0, \sigma_{\epsilon}^2 \mathbf{I}). \quad (\text{Equation 1})$$

Potential confounding covariates are assumed to be adjusted from the original protein abundance measures, resulting in the residuals \mathbf{E}_p . Both \mathbf{E}_p and columns of \mathbf{X} are standardized with mean 0 and variance 1.

When individual-level genetic and proteomic data from a reference panel are not available, OTTERS¹¹ can still estimate \mathbf{w} in *Equation 1* by using only the summary pQTL reference data that are generated based on the following single-variant linear regression models with standardized genotype vectors \mathbf{x}_j for genetic variants $j = 1, \dots, m$:

$$\mathbf{E}_p = \mathbf{x}_j w_j + \epsilon_j, \quad \epsilon_j \sim N(0, \sigma_{\epsilon_j}^2 \mathbf{I}). \quad (\text{Equation 2})$$

Summary pQTL reference data include the marginal least squared effect estimates ($\tilde{w}_j, j = 1, \dots, m$), sample size, and linkage disequilibrium coefficients in the reference pQTL cohort (which can also be approximated by using an external reference panel with the same ancestry). OTTERS employs five representative PRS models, including the P-value Thresholding with linkage disequilibrium (LD) clumping ($P+T$)¹⁷ with p-value thresholds of 0.05 ($P+T_{0.05}$) and 0.001 ($P+T_{0.001}$), frequentist LASSO regression model (*lassosum*)^{18,19}, nonparametric

Bayesian Dirichlet process regression model (*SDPR*)^{20,21}, and Bayesian multiple linear regression model with continuous shrinkage prior (*PRS-CS*)²². These PRS models will estimate five sets of pQTL weights ($\hat{\mathbf{w}}$) for each protein-coding gene per tissue type.

In Stage II, OTTERS first uses these five sets of pQTL weights ($\hat{\mathbf{w}}$) from Stage I as variant weights (*Equation 3*) to test gene-based association with respect to the phenotype in the summary-level GWAS test data. The test statistic can be written as

$$Z_p = \frac{\sum_{j=1}^m (\hat{w}_j Z_j)}{\sqrt{\hat{\mathbf{w}}' \mathbf{V} \hat{\mathbf{w}}}}, \quad (\text{Equation 3})$$

where Z_j denotes the single-variant Z-score test statistic in GWAS summary data for the j^{th} genetic variant, and \mathbf{V} denotes the genotype correlation matrix that could be obtained from an external reference panel of the same ancestry as the test GWAS data⁸. Such gene-based association test has been shown to be equivalent as testing the association between predicted genetically regulated protein abundances and the phenotype in the GWAS test data^{7,8,23}.

Since the performance of a PRS model depends on the unknown genetic architecture of protein abundances, OTTERS aggregates the PWAS p-values based on all five PRS models by using the aggregated Cauchy association test (ACAT)²⁴. An omnibus test p-value is derived for each protein-coding gene, which is then used to identify significant PWAS risk genes¹¹.

Applying OTTERS to conduct PWAS of AD dementia

We first applied OTTERS¹¹ to estimate pQTL weights from the recently released summary pQTL data of brain (n=380), CSF (n=835), and plasma (n=529)¹². These summary pQTL data were generated by using proteomic data of individuals with AD and cognitively normal individuals of European ancestry profiled from an aptamer-based platform²⁵. These summary pQTL data were generated for 1079 proteins in brain, 731 proteins in CSF, and 931 proteins in plasma, and ~14M genetic variants with minor allele frequency (MAF) $\geq 2\%$. Linear regression models with protein abundances as the response variable, genotype of a single genetic variant as the test covariate, and additional adjusting covariates of age, sex, first two genotype principal components factors, and genotype platform, were used to generate the summary pQTL data. Since the summary pQTL data of these three tissues were generated by using samples of European ancestry, the LD information obtained from the whole genome sequencing data of

European samples from the ROS/MAP study⁹ was used to estimate pQTL weights, along with standardized marginal pQTL effect sizes and sample sizes.

For each protein in these three tissue types, we obtained five sets of estimated pQTL weights by five PRS models as implemented by OTTERS, which were used to conduct PWAS analyses with the recent GWAS summary data ($n \sim 789K$) of AD dementia³. The GWAS summary data of AD dementia³ were generated by meta-analysis, including clinically diagnosed AD cases and proxy AD and related dementia (proxy-ADD) cases from the UK Biobank (UKBB), resulting in a total of approximately 39,106 clinically diagnosed AD cases, 46,828 proxy-ADD cases, and 401,577 controls. By combining PWAS p-values based on five PRS models, the omnibus OTTERS p-values were obtained for each available protein in each of the three tissues. We corrected the omnibus OTTERS p-values per tissue by using the genomic control factor²⁶ to ensure that the median observed OTTERS p-value was adjusted to the expected value of 0.5 under the null hypothesis. We then used the adjusted nominal OTTERS p-values to calculate the false discovery rates (FDR, i.e., q-values) per tissue. Genes with q-values < 0.05 were identified as significant PWAS risk genes for AD dementia in the corresponding tissue.

Causal effects of PWAS risk genes by PMR-Egger

The two-stage PWAS framework does not distinguish genetic effects on phenotype that are mediated through genetically regulated protein abundances (i.e., causal effects or vertical pleiotropy effects), from shared genetic effects on protein abundances and phenotypes that are not mediated through protein abundances (i.e., horizontal pleiotropy effects). We further assessed the mediated causal effects of our identified significant PWAS risk genes by using the probabilistic Mendelian randomization (PMR-Egger) tool²⁷. PMR-Egger can assess causal mediated genetic effects while controlling for horizontal pleiotropy effects by using summary pQTL and GWAS data. The reference LD derived from the ROS/MAP WGS data was also used for implementing PMR-Egger.

PPI network and enrichment analyses by STRING

The STRING²⁸⁻³⁰ webtool integrates public data sources of protein interaction and analyzes the protein-protein interaction (PPI) network connectivity of proteins. Protein-protein

edges represent the functional association, colored with six different connections — curated databases, experiments, text mining, co-expression, gene co-occurrence and protein homology. Gene co-occurrence association predictions are based on whole-genome comparisons. The STRING²⁸ webtool also provides gene enrichment analysis with respect to Gene Ontologies (GO)³¹ annotations. Enrichment analysis aims to detect GO terms and pathways that are significantly enriched with genes in the network versus random genes. The enrichment strength is provided along with FDR, which indicates the ratio between the number of proteins in the network that are annotated with a term and the number of proteins that expected to be annotated with this term in a random network of the same size. In this study, we utilized the STRING webtool to conduct PPI network and enrichment analyses with the list of PWAS risk genes identified by OTTERS in all three tissues.

TWAS of AD dementia

We also conducted TWAS of AD dementia by using the same GWAS summary data of AD dementia³ and the reference transcriptomic data of 931 DLPFC samples from the ROS/MAP studies⁹. ROS and MAP are two ongoing longitudinal studies of aging and Alzheimer's disease. Both studies enroll participants without known dementia, who agree to annual clinical evaluations and brain donation upon death. Transcriptomic data of 931 DLPFC samples from the ROS/MAP studies were profiled by RNA-sequencing. Gene expression data were quantified by transcripts per million (TPM), log₂ transformed, and adjusted for confounding covariates, including age, sex, postmortem interval, batch effects, and 20 PEER factors. Quality-controlled ROS/MAP WGS data were used for TWAS, where common genetic variants with minor allele frequency (MAF) > 1% and Hardy-Weinberg p-value > 10⁻⁵ were analyzed. Cis- genetic variants within 1Mb of each gene's flanking regions were used in the gene expression imputation models as predictors. Reference LD derived from ROS/MAP WGS samples of European ancestry were used in the TWAS.

For each gene, three TWAS tools including TIGAR, PrediXcan, and FUSION were utilized for estimating eQTL weights in Stage I. The Stage II TWAS results of AD dementia were obtained by using the eQTL weights estimated by each of the TWAS tool, which were combined by the ACAT method¹⁰. The combined omnibus TWAS p-values were adjusted for the

genomic control factor²⁶, and then used to derive FDR q-values. Significant TWAS risk genes were identified with q-values < 0.05.

Results

PWAS results of AD dementia by OTTERS

By applying OTTERS¹¹ to the summary pQTL reference data of three tissues (brain, CSF and plasma)⁵ and recent large-scale GWAS summary data of AD dementia, we obtained PWAS p-values with pQTL weights estimated by five complimentary PRS models (see Methods). Moderate inflation was observed in the Quantile-Quantile (Q-Q) plots of these proteome-wide p-values in all three tissues (**Fig. S1-S3**). Omnibus OTTERS p-values were obtained by combining the PWAS p-values across all 5 PRS methods²⁴, and then were adjusted by the genomic control factor²⁶. The adjusted OTTERS p-values were used to calculate FDR q-values to account for multiple testing. We identified 30 PWAS significant risk genes of AD dementia with OTTERS FDR q-value < 0.05, including 11, 9, and 16 genes respectively detected in brain, CSF, and plasma tissues (**Fig. 1; Table 1**), with 4 detected in at least two tissues, and gene *MAPK3* detected in all three tissues.

As shown in **Table 1**, we found 11 out of 30 PWAS significant genes (labeled in **Fig. 1**), such as *BCAM*³², *APOE*³³, *IL19*³⁴, and *IL34*³⁵, were detected by previous GWAS of AD or AD pathological hallmarks as shown in GWAS Catalog³⁶. We also found 2 of these PWAS risk genes (labeled in **Fig. 1**) identified in brain (*APOE*, *APOM*), 2 in CSF (*AIF1*, *BCAM*), and 2 in plasma (*APOM*, *BCAM*) were identified by previous PWAS of AD dementia using individual-level proteomic data profiled from DLPFC tissue of the ROS/MAP cohorts¹⁰.

Additionally, our analysis identified 9 novel PWAS risk genes (labeled in **Fig. 1**) that are not previously associated with AD dementia by GWAS, TWAS or PWAS — *CSF1R*, *MAPK3* and *LILRB1* in brain; *ALDOA* and *MAPK3* in CSF; *PROC*, *MAPKAPK3*, *FAM3D*, *MAPK3*, *NTF4*, and *CEBPB* in plasma. AD relevant biological functions were reported for these novel findings. Especially, *CSF1R* that encodes the tyrosine kinase receptor *CSF1R* was associated with microglial homeostasis and neuronal survival, implicating its dysfunction in increasing risks for AD³⁷. *LILRB1* that encodes a receptor for soluble β -amyloid (A β) oligomers was found as a potential contributor to synaptic loss and cognitive deficits in AD³⁸. Alterations in *ALDOA*,

implicated in oxidative neurotoxicity, were found to contribute to the pathogenesis of Alzheimer's disease³⁹. *PROC* is involved in the neurodegenerative process, showing an inverse association with incident dementia⁴⁰. The stress-responsive kinase *MAPKAPK3*, a downstream target of *MAPK14*, was implicated in the regulation of autophagy and might play a role in AD pathology by modulating the degradation of proteins involved in amyloid plaque formation⁴¹. *FAM3D* was found involved in neuroinflammatory pathways and microglial responses in early AD stage⁴². The neurotrophic factor *NTF4*, was shown to play a role in early neurodegenerative changes and cognitive decline in AD⁴³. The transcription factor *C/EBPβ*, encoded by *CEBPB*, has been implicated in the regulation of *APOE* expression⁴⁴. The gene *MAPK3* detected in all three tissues is involved in immune system processes, which was found to be activated in AD brains and involved in pathogenesis of AD including tau phosphorylation and amyloid deposition⁴⁵.

Comparison of different PRS models

As described in the Methods section, OTTERS leverages all 5 complimentary PRS model (*P+T_0.001*, *P+T_0.05*, *lassosum*, *SDPR*, and *PRS-CS*) to account for complex genetic architecture underlying the protein abundance quantitative traits, thus improving the PWAS power for studying complex diseases. Here, we compared the omnibus OTTERS p-values to the PWAS p-values obtained by each individual PRS methods (**Table 1**). As pointed out by the OTTERS paper¹¹, we found that all individual PRS models contributed to the omnibus OTTERS results. For example, the well-known AD risk gene *APOE* in brain was detected by all PRS models except *P+T_0.001*, and gene *BCAM* in CSF that is proximate to *APOE* was detected by *P+T_0.05*, *PRS-CS*, and *SDPR*. To investigate how individual PRS models contribute to the final OTTERS results, we plotted the pQTL weights estimated by all five PRS models for three example PWAS risk genes (*APOE*, *BSG*, and *PROC*) that were respectively detected in brain, CSF, and plasma tissues by OTTERS (**Fig. 2**). We plotted these pQTL weights with colors corresponding to $-\log_{10}$ (GWAS p-values).

In **Fig. 2A**, we showed pQTL weights for *APOE* in brain, which was found significant by *lassosum* (p-value = 1.23e-10), *P+T_0.05* (p-value = 1.23e-05), *PRS_CS* (p-value = 1.35e-05), and *SDPR* (p-value = 8.45e-07). We found that the significance of gene *APOE* was driven by GWAS significant SNPs located in *TOMM40* and *NECTIN2*, with non-zero pQTL weights

estimated by these PRS methods. Most genetic variants with “significant” GWAS p-values were excluded by $P+T_{0.01}$ due to their pQTL p-values > 0.001 . Interestingly, genes *TOMM40* and *NECTIN2* are proximal to *APOE*. *TOMM40* is a known risk gene of AD dementia¹ and has been associated with family history of AD⁴⁶. *NECTIN2* was previously reported as a GWAS risk gene for beta-amyloid 1-42³⁵, low-density lipoprotein cholesterol level interaction, and short total sleep time⁴⁷.

In **Fig. 2B**, we showed pQTL weights of gene *BSG* in CSF, which was detected by *lassosum* (p-value = 1.54e-05), *PRS-CS* (p-value = 3.07e-04), and *SDPR* (p-value = 9.96e-05). Compared to the $P+T$ models, these PRS methods all estimated non-zero pQTL weights for more GWAS significant SNPs in the test region. In **Fig 2C**, we showed pQTL weights of gene *PROC* in plasma, which was only detected by *PRS-CS* (p-value = 4.31e-05) and *SDPR* (p-value = 9.10e-04). *lassosum* estimated pQTL weights with higher magnitude for “non-significant” GWAS SNPs (GWAS p-values $> 1e-5$, black dots) in the test region, and most “significant” GWAS SNPs were filtered out by the $P+T$ models due to their pQTL p-values > 0.001 .

Additionally, we plotted the pQTL weights of another 3 significant PWAS risk genes — *APOM* in brain (**Fig. S4**), *AIF1* in CSF (**Fig. S5**), and *NCR2* in plasma (**Fig. S6**). *APOM* (p-value = 2.42e-08 in brain) and *AIF1* (p-value = 1.22e-08 in CSF) were found significant only by *lassosum*, which estimated pQTL weights in relatively higher magnitude for “significant” GWAS SNPs. *NCR2* (in plasma) were found significant by all PRS methods except $P+T_{0.001}$ that estimated non-zero pQTL weights for “significant” GWAS SNPs.

Overall, these plots of pQTL weights demonstrated that significant PWAS risk genes were mainly driven by test genetic variants that had non-zero pQTL weights with relatively large magnitudes and had “significant” GWAS p-values (e.g., $< 10e-05$). These pQTL weight plots also showed that OTTERS leveraged the strength of all complementary PRS methods to achieve higher power.

Mediated causal effects of PWAS risk genes

We employed the probabilistic Mendelian Randomization tool, PMR-Egger²⁷, to assess if the genetic effects of these 30 PWAS risk genes were mediated through genetically regulated protein abundances and causal for AD dementia, while accounting for possible horizontal pleiotropy effects (Methods). As shown in **Table 1**, we found that 4 out of 11 (36.4%) PWAS

risk genes in brain, 6 out of 9 (66.7%) PWAS risk genes in CSF, 4 out of 16 (25.0%) PWAS risk genes in plasma tissues had significant mediated causal genetic effects with $FDR < 0.05$ without significant horizontal pleiotropy effects. Additionally, we found 3 PWAS risk genes in plasma with significant mediated causal genetic effects that also had significant horizontal pleiotropy effects with $FDR < 0.05$. In summary, by PMR-Egger, we validated causal genetic effects that were mediated through genetically regulated protein abundances for 13 (43.3%) out of these 30 PWAS risk genes in brain, CSF, and plasma tissues by OTTERS.

PPI network and enrichment analyses

By using the STRING²⁸ webtool (Methods), we found 25 out of these 30 significant PWAS risk genes identified by OTTERS were interconnected in a network involving the well-known AD risk gene *APOE* (**Fig. 3**). The edges of the network were colored according to the protein-protein interactions (PPI) based on different data sources. The STRING webtool also provided gene enrichment analyses results with these PWAS risk genes (**Fig. 3**).

We found that our identified 30 PWAS risk genes were enriched in gene ontology (GO) pathways of immune response (*AZU1, CSF1R, CXCL16, CEBPB, HAVCR2, LILRB1, NCR3, AIF1, IL34, LTA, ELANE, PRKCB, IL19*) with enrichment $FDR = 5.23e-07$ and strength = 0.81, glial cell proliferation (*CSF1R, CEBPB, IL34*) with enrichment $FDR = 0.0038$ and strength = 1.86, regulation of cell migration (*APOE, MAPK3, CSF1R, CXCL16, BSG, AIF1, IL34, ELANE*) with enrichment $FDR = 0.0105$ and strength = 0.75, regulation of cell-cell adhesion (*CEBPB, HAVCR2, LILRB1, PLAUR, AIF1, ELANE*) with enrichment $FDR = 0.0131$ and strength = 2.27, high-density lipoprotein particle clearance (*APOE, APOM*) with enrichment $FDR = 0.0131$ and strength = 0.91, as well as positive regulation of protein metabolic process (*AZU1, APOE, MAPK3, CSF1R, PLAUR, AIF1, IL34, ELANE, NTF4*) with enrichment $FDR = 0.0322$ and strength = 0.59. Also, we found that 14 of these PWAS risk genes were enriched in the Human Phenotype of blood protein measurement (e.g., *MAPK3, APOE, PRKCB*) with enrichment $FDR = 0.0014$ and strength = 0.71; and 15 of these were enriched in immune system (e.g., *IL34, NCR3, AZU1*) in the Reactome Pathway⁴⁸, with enrichment $FDR = 9.03e-05$ and strength = 0.7.

Particularly, the detected PPI network showed that the novel PWAS risk genes identified by OTTERS were closely interconnected with known risk genes of AD dementia. For example, novel PWAS risk gene *CEBPB* was connected with the known GWAS and TWAS risk gene

*PRKCB*⁴⁹ and was in the GO pathway of immune response. Novel risk genes *CSF1R* and *NTF4* were found connected with the known GWAS risk gene of AD dementia *IL34*⁵⁰ and were in the GO pathway of positive regulation of protein metabolic process.

Compare to TWAS results of AD dementia

Next, we compared our PWAS findings to the TWAS findings by using individual-level reference transcriptomic data of DLPFC from the ROS/MAP studies and the same GWAS summary data of AD dementia. As described in Methods, we utilized the omnibus TWAS approach¹⁰ by using the ACAT method²⁴ to combine the results obtained by individual TWAS tools of TIGAR/DPR, PrediXcan/Elastic-Net, and FUSION/BestModel.

The omnibus TWAS (TWAS-O) approach identified 113 significant risk genes of AD dementia with FDR q-value < 0.05 (**Fig. 4**), including a total of 17 independent significant genes (labeled in **Fig. 4**) that do not have shared genetic variants in their test regions (± 1 MB around the test transcription starting/termination sites of the protein-coding gene). These independent significant genes were curated as having no overlapped test genetic variants. Importantly, 18 out of our identified 30 PWAS risk genes were either identified by TWAS-O or located within the shared (1Mb) test regions of the risk genes identified by TWAS-O, including 7 out of 11 in brain, 6 out of 9 in CSF, and 9 out of 16 in plasma tissues.

For example, the PWAS risk gene *IDUA* in brain has shared test genetic variants as the TWAS-O risk gene *CPLX1* (q-value = $6.31e-03$), whose downregulation is likely to influence AD-associated neurodegeneration⁵¹. The PWAS risk gene *APOE* in brain has shared test genetic variants with 14 nearby TWAS-O risk genes on chromosome 19. PWAS risk genes *AIF1* and *CLIC1* in CSF have shared test genetic variants with the same set of 8 TWAS-O risk genes, which include *HLA-DRB1*, a known risk gene of late-onset Alzheimer's disease (LOAD), particularly in APOE $\epsilon 4$ non-carrier population⁵². PWAS risk gene *BCAM* in both CSF and plasma tissues has overlapped test genetic variants with 18 TWAS-O risk genes, including *ZNF112*, *ZNF 221* and *ZNF 233* that are Zinc finger protein genes known with pathophysiological role in neuro-related diseases and disorders⁵³. PWAS risk gene *GFAP* in plasma has shared test genetic variants with 19 TWAS-O risk genes, including *MAPT* that encodes the tau protein with a critical role in neurodegeneration⁵⁴.

Discussion

We conducted PWAS of AD dementia with the recently released public data resources of summary pQTL data of brain, CSF, and plasma tissues¹² as well as GWAS summary data of AD dementia, by employing our recently developed OTTERS¹¹ tool. The distinction of our PWAS analyses from previous ones lies in the use of summary pQTL reference data from multiple tissues (brain, CSF, and plasma) related to neurodegenerative disorders. CSF and plasma are two bodily fluids believed to contain the richest source of biomarkers of AD and play important roles in research of AD pathology⁵⁵. CSF surrounds the central nervous system (CNS) and is a highly representative and obtainable fluid for detecting brain pathologies. Blood plasma contains proteins that affect brain functions from the periphery, as well as proteins exported from the brain⁵⁵. Especially, recent studies have shown that amyloid beta and phosphorylated tau presenting in CSF and plasma could be used as biomarkers for detecting AD dementia in early stages¹³⁻¹⁶. Therefore, our PWAS results leveraging proteomic data of plasma and CSF tissues in addition to brain tissue are expected to reveal additional important risk genes of AD, whose genetic effects are mediated through protein abundances in biofluids, thus providing valuable insights into future biomarker discovery of AD dementia.

We identified 30 PWAS risk genes whose genetic effects were potentially mediated through genetically regulated protein abundances, including 11 in brain, 9 in CSF and 16 in plasma tissues. We found OTTERS gained power by leveraging multiple complementary PRS models to estimate pQTL weights and by considering reference pQTL data of multiple tissues. Specifically, we showed that each PRS model made distinct and considerable contributions to the final omnibus PWAS results by OTTERS.

Previous studies have highlighted notable biological roles for our identified PWAS risk genes in three tissues, including significant enrichment in the GO biological pathways of immune system processes and lipoprotein metabolism. For example, PWAS risk gene *APOE* in brain is a known major risk factor for AD dementia⁵⁶, which has a crucial function in the central nervous system⁵⁷. The PWAS risk gene *APOM* in brain and plasma codes for an apolipoprotein associated with AD dementia and has been implicated in the lipid processing pathway⁵⁸. The PWAS risk gene *AIF1* in CSF has been associated with the activation of microglia (a type of immune cell localized throughout the central nervous system)⁵⁹, which is a key player in the response to central nervous disorders such as AD⁶⁰.

Besides known AD risk genes, our PWAS also identified 9 novel risk genes that are not detected by previous GWAS, TWAS, or PWAS. Especially, 6 out of these 9 novel PWAS risk genes were connected with known AD risk genes in the PPI network. Novel PWAS risk genes *CSF1R*, *LILRB1*, and *CEBPB* are enriched in the pathway of immune response, along with previously known AD risk genes.

These previous findings, results from Mendelian Randomization analysis using by PMR-Egger, and PPI network analysis results collectively demonstrate the significance of our identified PWAS risk genes in three tissues. Further experimental studies about the functions of our findings are essential but out of the scope of this work.

PWAS analysis by the OTTERS tool still has its limitations. First, we only consider *cis*-pQTL within the $\pm 1Mb$ region around the transcription start/termination sites of the corresponding protein-coding gene. Second, the two-stage PWAS cannot account for possible horizontal pleiotropy genetic effects (those directly affecting the phenotype of interest) when testing if the genetic effects are mediated through genetically regulated protein abundances. Although the PMR-Egger tool can account for horizontal pleiotropy genetic effects, the computation burden of the PMR-Egger tool impedes its application to testing the protein-coding genes of proteome-wide proteins (average 60 vs. 2 CPU minutes per protein-coding gene by OTTERS). Thus, we only applied the PMR-Egger²⁷ tool to our identified 30 PWAS risk genes.

Conclusions

In conclusion, we presented the first PWAS analysis of AD dementia utilizing the summary pQTL reference data of multiple tissues related to neurodegenerative disorders. Our identified PWAS risk genes provide candidate proteins in biofluids such as CSF and plasma and brain tissues for follow-up functional experiments and targeted therapeutic development of AD dementia. Previous studies, validation results from Mendelian Randomization analysis by PMR-Egger, and PPI network analysis all demonstrated the significance of our identified PWAS risk genes in these three tissues. Further experimental studies about the functions of our findings are essential. Additionally, this study showed the practical usefulness of the OTTERS tool in leveraging publicly available summary pQTL data and GWAS data resources to conduct PWAS of complex diseases.

List of Abbreviations

1. PWAS - Proteome-wide association study
2. GWAS - Genome-wide association study
3. AD - Alzheimer's disease
4. pQTL - Protein quantitative trait loci
5. CSF - Cerebrospinal fluid
6. PRS - Polygenic risk score
7. ACAT - Aggregated Cauchy association test
8. PPI - Protein-protein interaction
9. PMR-Egger - Probabilistic Mendelian randomization Egger
10. TWAS - Transcriptome-wide association study
11. DLPFC - Dorsolateral prefrontal cortex
12. WGS - Whole genome sequencing
13. proxy-ADD - proxy AD and related dementia
14. UKBB - UK Biobank
15. LD - Linkage disequilibrium
16. FDR - False discovery rate
17. ROS/MAP - Religious Orders Study and Memory and Aging Project
18. GO - Gene Ontologies
19. MAF - Minor allele frequency
20. TPM - Transcripts per million
21. PEER - Probabilistic estimation of expression residuals

Declarations

Ethics approval and consent to participate

Summary-level pQTL data of brain, CSF, and plasma, and summary GWAS data of AD dementia were used for conducting PWAS in this study. These data are de-identified and publicly available, requiring no ethics approval. All de-identified omics data are not considered as human data per NIH guidelines.

All ROSMAP participants enrolled without known dementia and agreed to detailed clinical evaluation and brain donation at death [<https://pubmed.ncbi.nlm.nih.gov/29865057/>]. Both studies were approved by an Institutional Review Board of Rush University Medical Center (ROS IRB# L91020181, MAP IRB# L86121802). Both studies were conducted according to the principles expressed in the Declaration of Helsinki. Each participant signed an informed consent, Anatomic Gift Act, and an RADC Repository consent (IRB# L99032481) allowing her data and biospecimens to be repurposed. ROS/MAP transcriptomic and whole genome sequencing data used for TWAS in this study were shared with a data use agreement.

Consent for publication

Not applicable.

Availability of data and materials

GWAS summary data of AD dementia is available from². Summary-level pQTL data of brain, CSF, and plasma tissues can be accessed by emailing niagads@pennterms.upenn.edu to set up an FTP transfer of the data. Omics data from ROS/MAP cohorts are available with approved access from <https://doi.org/10.7303/syn10901595>. OTTERS tool is available from <https://github.com/daiqile96/OTTERS>. PMR tool is available from <https://github.com/yuanzhongshang/PMR>. The code used in this study for conducting PWAS of AD dementia are available from GitHub https://github.com/tingyhu45/PWAS_OTTERS. Trained pQTL weights by five PRS methods and our PWAS summary data will be deposited to SYNAPSE once this work is accepted. ROSMAP data can be requested at www.radc.rush.edu and www.synapse.org.

Competing interests

The authors declare no competing financial interests relative to the present study.

Funding

This work was supported by the National Institutes of Health (NIH), National Institute of General Medical Sciences (NIGMS, R35GM138313, for J.Y), and National Institute on Aging (NIA, AG071170, for M.P.E.). ROSMAP is supported by P30AG10161, P30AG72975, R01AG15819, R01AG17917, U01AG46152, and U01AG61356.

Authors' contributions

T.H. and Q.L. conducted data analysis and drafted manuscript. Q.D. and R.L.P. participated in data analysis and data interpretation, and revised manuscript. M.P.E. supervised data analysis, data interpretation, and revised manuscript. J.Y. conceived this study, supervised data analysis, data interpretation, and revised manuscript.

References

1. Jansen, I.E., Savage, J.E., Watanabe, K., Bryois, J., Williams, D.M., Steinberg, S., Sealock, J., Karlsson, I.K., Hägg, S., Athanasiu, L., et al. (2019). Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease risk. *Nature Genetics* 51, 404-413. [10.1038/s41588-018-0311-9](https://doi.org/10.1038/s41588-018-0311-9).
2. Wightman, D.P., Jansen, I.E., Savage, J.E., Shadrin, A.A., Bahrami, S., Holland, D., Rongve, A., Børte, S., Winsvold, B.S., Drange, O.K., et al. (2021). A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer's disease. *Nature Genetics* 53, 1276-1282. [10.1038/s41588-021-00921-z](https://doi.org/10.1038/s41588-021-00921-z).
3. Bellenguez, C., Küçükali, F., Jansen, I.E., Kleindam, L., Moreno-Grau, S., Amin, N., Naj, A.C., Campos-Martin, R., Grenier-Boley, B., Andrade, V., et al. (2022). New insights into the genetic etiology of Alzheimer's disease and related dementias. *Nature Genetics* 54, 412-436. [10.1038/s41588-022-01024-z](https://doi.org/10.1038/s41588-022-01024-z).
4. Wingo, A.P., Liu, Y., Gerasimov, E.S., Gockley, J., Logsdon, B.A., Duong, D.M., Dammer, E.B., Robins, C., Beach, T.G., Reiman, E.M., et al. (2021). Integrating human brain proteomes with genome-wide association data implicates new proteins in Alzheimer's disease pathogenesis. *Nature Genetics* 53, 143-146. [10.1038/s41588-020-00773-z](https://doi.org/10.1038/s41588-020-00773-z).
5. Brandes, N., Linial, N., and Linial, M. (2020). PWAS: proteome-wide association study—linking genes and phenotypes by functional variation in proteins. *Genome Biology* 21. [10.1186/s13059-020-02089-x](https://doi.org/10.1186/s13059-020-02089-x).
6. Nagpal, S., Meng, X., Epstein, M.P., Tsoi, L.C., Patrick, M., Gibson, G., De Jager, P.L., Bennett, D.A., Wingo, A.P., Wingo, T.S., and Yang, J. (2019). TIGAR: An Improved Bayesian Tool for Transcriptomic Data Imputation Enhances Gene Mapping of Complex Traits. *The American Journal of Human Genetics* 105, 258-266. [10.1016/j.ajhg.2019.05.018](https://doi.org/10.1016/j.ajhg.2019.05.018).
7. Gamazon, E.R., Wheeler, H.E., Shah, K.P., Mozaffari, S.V., Aquino-Michaels, K., Carroll, R.J., Eyler, A.E., Denny, J.C., Nicolae, D.L., Cox, N.J., and Im, H.K. (2015). A gene-based association method for mapping traits using reference transcriptome data. *Nature Genetics* 47, 1091-1098. [10.1038/ng.3367](https://doi.org/10.1038/ng.3367).
8. Gusev, A., Ko, A., Shi, H., Bhatia, G., Chung, W., Penninx, B.W.J.H., Jansen, R., De Geus, E.J.C., Boomsma, D.I., Wright, F.A., et al. (2016). Integrative approaches for large-scale transcriptome-wide association studies. *Nature Genetics* 48, 245-252. [10.1038/ng.3506](https://doi.org/10.1038/ng.3506).
9. Bennett, D.A., Buchman, A.S., Boyle, P.A., Barnes, L.L., Wilson, R.S., and Schneider, J.A. (2018). Religious Orders Study and Rush Memory and Aging Project. *Journal of Alzheimer's Disease* 64, S161-S189. [10.3233/jad-179939](https://doi.org/10.3233/jad-179939).
10. Hu, T., Parrish, R.L., Dai, Q., Buchman, A.S., Tasaki, S., Bennett, D.A., Seyfried, N.T., Epstein, M.P., and Yang, J. Omnibus proteome-wide association study identifies 43 risk genes for Alzheimer disease dementia. *The American Journal of Human Genetics*. [10.1016/j.ajhg.2024.07.001](https://doi.org/10.1016/j.ajhg.2024.07.001).
11. Dai, Q., Zhou, G., Zhao, H., Vösa, U., Franke, L., Battle, A., Teumer, A., Lehtimäki, T., Raitakari, O.T., Esko, T., et al. (2023). OTTERS: a powerful TWAS framework leveraging summary-level reference data. *Nature Communications* 14. [10.1038/s41467-023-36862-w](https://doi.org/10.1038/s41467-023-36862-w).

12. Yang, C., Farias, F.H.G., Ibanez, L., Suhy, A., Sadler, B., Fernandez, M.V., Wang, F., Bradley, J.L., Eiffert, B., Bahena, J.A., et al. (2021). Genomic atlas of the proteome from brain, CSF and plasma prioritizes proteins implicated in neurological disorders. *Nature Neuroscience* *24*, 1302-1312. [10.1038/s41593-021-00886-6](https://doi.org/10.1038/s41593-021-00886-6).
13. Paraskevas, G.P., and Kapaki, E. (2021). Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in the Era of Disease-Modifying Treatments. *Brain Sciences* *11*, 1258. [10.3390/brainsci11101258](https://doi.org/10.3390/brainsci11101258).
14. Bouwman, F.H., Frisoni, G.B., Johnson, S.C., Chen, X., Engelborghs, S., Ikeuchi, T., Paquet, C., Ritchie, C., Bozeat, S., Quevenco, F.C., and Teunissen, C. (2022). Clinical application of CSF biomarkers for Alzheimer's disease: From rationale to ratios. *Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring* *14*. [10.1002/dad2.12314](https://doi.org/10.1002/dad2.12314).
15. Pais, M.V., Forlenza, O.V., and Diniz, B.S. (2023). Plasma Biomarkers of Alzheimer's Disease: A Review of Available Assays, Recent Developments, and Implications for Clinical Practice. *Journal of Alzheimer's Disease Reports* *7*, 355-380. [10.3233/adr-230029](https://doi.org/10.3233/adr-230029).
16. Altomare, D., Stampacchia, S., Ribaldi, F., Tomczyk, S., Chevalier, C., Poulain, G., Asadi, S., Bancila, B., Marizzoni, M., Martins, M., et al. (2023). Plasma biomarkers for Alzheimer's disease: a field-test in a memory clinic. *Journal of Neurology, Neurosurgery & Psychiatry* *94*, 420-427. [10.1136/jnnp-2022-330619](https://doi.org/10.1136/jnnp-2022-330619).
17. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. (2009). *Nature* *460*, 748-752. [10.1038/nature08185](https://doi.org/10.1038/nature08185).
18. Mak, T.S.H., Porsch, R.M., Choi, S.W., Zhou, X., and Sham, P.C. (2017). Polygenic scores via penalized regression on summary statistics. *Genetic Epidemiology* *41*, 469-480. [10.1002/gepi.22050](https://doi.org/10.1002/gepi.22050).
19. Tibshirani, R. (1996). Regression Shrinkage and Selection via the Lasso. *Journal of the Royal Statistical Society. Series B (Methodological)* *58*, 267-288.
20. Zhou, G., and Zhao, H. (2021). A fast and robust Bayesian nonparametric method for prediction of complex traits using summary statistics. *PLOS Genetics* *17*, e1009697. [10.1371/journal.pgen.1009697](https://doi.org/10.1371/journal.pgen.1009697).
21. Zeng, P., and Zhou, X. (2017). Non-parametric genetic prediction of complex traits with latent Dirichlet process regression models. *Nature Communications* *8*. [10.1038/s41467-017-00470-2](https://doi.org/10.1038/s41467-017-00470-2).
22. Ge, T., Chen, C.-Y., Ni, Y., Feng, Y.-C.A., and Smoller, J.W. (2019). Polygenic prediction via Bayesian regression and continuous shrinkage priors. *Nature Communications* *10*. [10.1038/s41467-019-09718-5](https://doi.org/10.1038/s41467-019-09718-5).
23. Tang, S., Buchman, A.S., De Jager, P.L., Bennett, D.A., Epstein, M.P., and Yang, J. (2021). Novel Variance-Component TWAS method for studying complex human diseases with applications to Alzheimer's dementia. *PLOS Genetics* *17*, e1009482. [10.1371/journal.pgen.1009482](https://doi.org/10.1371/journal.pgen.1009482).
24. Liu, Y., Chen, S., Li, Z., Morrison, A.C., Boerwinkle, E., and Lin, X. (2019). ACAT: A Fast and Powerful p Value Combination Method for Rare-Variant Analysis in Sequencing Studies. *The American Journal of Human Genetics* *104*, 410-421. [10.1016/j.ajhg.2019.01.002](https://doi.org/10.1016/j.ajhg.2019.01.002).
25. Gold, L., Ayers, D., Bertino, J., Bock, C., Bock, A., Brody, E.N., Carter, J., Dalby, A.B., Eaton, B.E., Fitzwater, T., et al. (2010). Aptamer-Based Multiplexed Proteomic

- Technology for Biomarker Discovery. *PLoS ONE* 5, e15004. 10.1371/journal.pone.0015004.
26. Devlin, B., Roeder, K., and Wasserman, L. (2001). Genomic Control, a New Approach to Genetic-Based Association Studies. *Theoretical Population Biology* 60, 155-166. <https://doi.org/10.1006/tpbi.2001.1542>.
 27. Yuan, Z., Zhu, H., Zeng, P., Yang, S., Sun, S., Yang, C., Liu, J., and Zhou, X. (2020). Testing and controlling for horizontal pleiotropy with probabilistic Mendelian randomization in transcriptome-wide association studies. *Nature Communications* 11. 10.1038/s41467-020-17668-6.
 28. Szklarczyk, D., Gable, A.L., Lyon, D., Junge, A., Wyder, S., Huerta-Cepas, J., Simonovic, M., Doncheva, N.T., Morris, J.H., Bork, P., et al. (2019). STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. *Nucleic Acids Research* 47, D607-D613. 10.1093/nar/gky1131.
 29. Szklarczyk, D., Gable, A.L., Nastou, K.C., Lyon, D., Kirsch, R., Pyysalo, S., Doncheva, N.T., Legeay, M., Fang, T., Bork, P., et al. (2021). The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets. *Nucleic Acids Research* 49, D605-D612. 10.1093/nar/gkaa1074.
 30. Szklarczyk, D., Kirsch, R., Koutrouli, M., Nastou, K., Mehryary, F., Hachilif, R., Gable, A.L., Fang, T., Nadezhda, Pyysalo, S., et al. (2023). The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. *Nucleic Acids Research* 51, D638-D646. 10.1093/nar/gkac1000.
 31. The Gene Ontology Resource: 20 years and still GOing strong. (2019). *Nucleic Acids Research* 47, D330-D338. 10.1093/nar/gky1055.
 32. Marioni, R.E., Harris, S.E., Zhang, Q., McRae, A.F., Hagenaars, S.P., Hill, W.D., Davies, G., Ritchie, C.W., Gale, C.R., Starr, J.M., et al. (2019). Correction: GWAS on family history of Alzheimer's disease. *Translational Psychiatry* 9. 10.1038/s41398-019-0498-2.
 33. Meda, S.A., Narayanan, B., Liu, J., Perrone-Bizzozero, N.I., Stevens, M.C., Calhoun, V.D., Glahn, D.C., Shen, L., Risacher, S.L., Saykin, A.J., and Pearlson, G.D. (2012). A large scale multivariate parallel ICA method reveals novel imaging-genetic relationships for Alzheimer's disease in the ADNI cohort. *NeuroImage* 60, 1608-1621. 10.1016/j.neuroimage.2011.12.076.
 34. Wang, X., Lopez, O., Sweet, R.A., Becker, J.T., Dekosky, S.T., Barmada, M.M., Feingold, E., Demirci, F.Y., and Kamboh, M.I. (2015). Genetic Determinants of Survival in Patients with Alzheimer's Disease. *Journal of Alzheimer's Disease* 45, 651-658. 10.3233/jad-142442.
 35. Chung, J., Wang, X., Maruyama, T., Ma, Y., Zhang, X., Mez, J., Sherva, R., Takeyama, H., Lunetta, K.L., Farrer, L.A., and Jun, G.R. (2018). Genome-wide association study of Alzheimer's disease endophenotypes at prediagnosis stages. *Alzheimer's & Dementia* 14, 623-633. 10.1016/j.jalz.2017.11.006.
 36. Buniello, A., Jacqueline, A., Cerezo, M., Harris, L.W., Hayhurst, J., Malangone, C., McMahon, A., Morales, J., Mountjoy, E., Sollis, E., et al. (2019). The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. *Nucleic Acids Research* 47, D1005-D1012. 10.1093/nar/gky1120.

37. Hu, B., Duan, S., Wang, Z., Li, X., Zhou, Y., Zhang, X., Zhang, Y.W., Xu, H., and Zheng, H. (2021). Insights Into the Role of CSF1R in the Central Nervous System and Neurological Disorders. *Front Aging Neurosci* *13*, 789834. [10.3389/fnagi.2021.789834](https://doi.org/10.3389/fnagi.2021.789834).
38. Kim, T., Vidal, G.S., Djurisic, M., William, C.M., Birnbaum, M.E., Garcia, K.C., Hyman, B.T., and Shatz, C.J. (2013). Human LILRB2 Is a β -Amyloid Receptor and Its Murine Homolog PirB Regulates Synaptic Plasticity in an Alzheimer's Model. *Science* *341*, 1399-1404. [10.1126/science.1242077](https://doi.org/10.1126/science.1242077).
39. Henriques, A.G., Müller, T., Oliveira, J.M., Cova, M., Da Cruz E Silva, C.B., and Da Cruz E Silva, O.A.B. (2016). Altered protein phosphorylation as a resource for potential AD biomarkers. *Scientific Reports* *6*, 30319. [10.1038/srep30319](https://doi.org/10.1038/srep30319).
40. Tin, A., Walker, K.A., Bressler, J., Windham, B.G., Griswold, M., Sullivan, K., Wu, A., Gottesman, R., Fornage, M., Coresh, J., et al. (2021). Association between Circulating Protein C Levels and Incident Dementia: The Atherosclerosis Risk in Communities Study. *Neuroepidemiology* *55*, 306-315. [10.1159/000516287](https://doi.org/10.1159/000516287).
41. Alam, J., and Scheper, W. (2016). Targeting neuronal MAPK14/p38 α activity to modulate autophagy in the Alzheimer disease brain. *Autophagy* *12*, 2516-2520. [10.1080/15548627.2016.1238555](https://doi.org/10.1080/15548627.2016.1238555).
42. Duggan, M.R., Gomez, G.T., Joynes, C.M., Bilgel, M., Chen, J., Fattorelli, N., Hohman, T.J., Mancuso, R., Cordon, J., Castellano, T., et al. (2024). Proteome-wide analysis identifies plasma immune regulators of amyloid-beta progression. *Brain, Behavior, and Immunity* *120*, 604-619. <https://doi.org/10.1016/j.bbi.2024.07.002>.
43. Ginsberg, S.D., Malek-Ahmadi, M.H., Alldred, M.J., Che, S., Elarova, I., Chen, Y., Jeanneteau, F., Kranz, T.M., Chao, M.V., Counts, S.E., and Mufson, E.J. (2019). Selective decline of neurotrophin and neurotrophin receptor genes within CA1 pyramidal neurons and hippocampus proper: Correlation with cognitive performance and neuropathology in mild cognitive impairment and Alzheimer's disease. *Hippocampus* *29*, 422-439. [10.1002/hipo.22802](https://doi.org/10.1002/hipo.22802).
44. Xia, Y., Wang, Z.-H., Zhang, J., Liu, X., Yu, S.P., Ye, K.X., Wang, J.-Z., Ye, K., and Wang, X.-C. (2021). C/EBP β is a key transcription factor for APOE and preferentially mediates ApoE4 expression in Alzheimer's disease. *Molecular Psychiatry* *26*, 6002-6022. [10.1038/s41380-020-00956-4](https://doi.org/10.1038/s41380-020-00956-4).
45. Zhu, X., Lee, H.-g., Raina, A.K., Perry, G., and Smith, M.A. (2003). The Role of Mitogen-Activated Protein Kinase Pathways in Alzheimer's Disease. *Neurosignals* *11*, 270-281. [10.1159/000067426](https://doi.org/10.1159/000067426).
46. Marioni, R.E., Harris, S.E., Zhang, Q., McRae, A.F., Hagenaars, S.P., Hill, W.D., Davies, G., Ritchie, C.W., Gale, C.R., Starr, J.M., et al. (2018). GWAS on family history of Alzheimer's disease. *Translational Psychiatry* *8*. [10.1038/s41398-018-0150-6](https://doi.org/10.1038/s41398-018-0150-6).
47. Noordam, R., Bos, M.M., Wang, H., Winkler, T.W., Bentley, A.R., Kilpeläinen, T.O., De Vries, P.S., Sung, Y.J., Schwander, K., Cade, B.E., et al. (2019). Multi-ancestry sleep-by-SNP interaction analysis in 126,926 individuals reveals lipid loci stratified by sleep duration. *Nature Communications* *10*. [10.1038/s41467-019-12958-0](https://doi.org/10.1038/s41467-019-12958-0).
48. Milacic, M., Beavers, D., Conley, P., Gong, C., Gillespie, M., Griss, J., Haw, R., Jassal, B., Matthews, L., May, B., et al. (2024). The Reactome Pathway Knowledgebase 2024. *Nucleic Acids Research* *52*, D672-D678. [10.1093/nar/gkad1025](https://doi.org/10.1093/nar/gkad1025).
49. Sherva, R., Gross, A., Mukherjee, S., Koesterer, R., Amouyel, P., Bellenguez, C., Dufouil, C., Bennett, D.A., Chibnik, L., Cruchaga, C., et al. (2020). Genome-wide

- association study of rate of cognitive decline in Alzheimer's disease patients identifies novel genes and pathways. *Alzheimer's & Dementia* *16*, 1134-1145. <https://doi.org/10.1002/alz.12106>.
50. De Rojas, I., Moreno-Grau, S., Tesi, N., Grenier-Boley, B., Andrade, V., Jansen, I.E., Pedersen, N.L., Stringa, N., Zettergren, A., Hernández, I., et al. (2021). Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. *Nature Communications* *12*. 10.1038/s41467-021-22491-8.
 51. Jęško, H., Wiczorek, I., Wencel, P.L., Gąssowska-Dobrowolska, M., Lukiw, W.J., and Strosznajder, R.P. (2021). Age-Related Transcriptional Deregulation of Genes Coding Synaptic Proteins in Alzheimer's Disease Murine Model: Potential Neuroprotective Effect of Fingolimod. *Frontiers in Molecular Neuroscience* *14*. 10.3389/fnmol.2021.660104.
 52. Lu, R.-C., Yang, W., Tan, L., Sun, F.-R., Tan, M.-S., Zhang, W., Wang, H.-F., and Tan, L. (2017). Association of HLA-DRB1 polymorphism with Alzheimer's disease: a replication and meta-analysis. *Oncotarget* *8*, 93219-93226. 10.18632/oncotarget.21479.
 53. Bu, S., Lv, Y., Liu, Y., Qiao, S., and Wang, H. (2021). Zinc Finger Proteins in Neuro-Related Diseases Progression. *Frontiers in Neuroscience* *15*. 10.3389/fnins.2021.760567.
 54. Strang, K.H., Golde, T.E., and Giasson, B.I. (2019). MAPT mutations, tauopathy, and mechanisms of neurodegeneration. *Laboratory Investigation* *99*, 912-928. 10.1038/s41374-019-0197-x.
 55. Aluise, C.D., Sowell, R.A., and Butterfield, D.A. (2008). Peptides and proteins in plasma and cerebrospinal fluid as biomarkers for the prediction, diagnosis, and monitoring of therapeutic efficacy of Alzheimer's disease. *Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease* *1782*, 549-558. <https://doi.org/10.1016/j.bbadis.2008.07.008>.
 56. Kim, J., Basak, J.M., and Holtzman, D.M. (2009). The Role of Apolipoprotein E in Alzheimer's Disease. *Neuron* *63*, 287-303. 10.1016/j.neuron.2009.06.026.
 57. Saunders, A.M., Strittmatter, W.J., Schmechel, D., St. George-Hyslop, P.H., Pericak-Vance, M.A., Joo, S.H., Rosi, B.L., Gusella, J.F., Crapper-MacLachlan, D.R., Alberts, M.J., et al. (1993). Association of apolipoprotein E allele ϵ 4 with late-onset familial and sporadic Alzheimer's disease. *Neurology* *43*, 1467-1467. 10.1212/WNL.43.8.1467.
 58. Kunkle, B.W., Grenier-Boley, B., Sims, R., Bis, J.C., Damotte, V., Naj, A.C., Boland, A., Vronskaya, M., Van Der Lee, S.J., Amlie-Wolf, A., et al. (2019). Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A β , tau, immunity and lipid processing. *Nature Genetics* *51*, 414-430. 10.1038/s41588-019-0358-2.
 59. De Leon-Oliva, D., Garcia-Montero, C., Fraile-Martinez, O., Boaru, D.L., García-Puente, L., Rios-Parra, A., Garrido-Gil, M.J., Casanova-Martín, C., García-Honduvilla, N., Bujan, J., et al. (2023). AIF1: Function and Connection with Inflammatory Diseases. *Biology* *12*, 694. 10.3390/biology12050694.
 60. Woodburn, S.C., Bollinger, J.L., and Wohleb, E.S. (2021). The semantics of microglia activation: neuroinflammation, homeostasis, and stress. *Journal of Neuroinflammation* *18*. 10.1186/s12974-021-02309-6.

Figure legends


Figure 1. Manhattan plots of PWAS results (FDR q-values) of AD dementia by OTTERS in Brain (A), CSF (B), and Plasma (C) tissues. The $-\log_{10}(\text{q-values})$ were plotted on the y-axis, and $-\log_{10}(0.05)$ was plotted as the dashed horizontal line. Independent significant genes are labeled. Yellow triangles: genes identified by previous GWAS and TWAS; Blue triangles: genes identified by previous GWAS; Purple square: genes identified by previous TWAS; Red circle: novel findings.

Figure 2. Scatter plots of pQTL weights of example PWAS risk genes of *APOE* in brain, *BSG* in CSF, and *PROC* in plasma that were estimated by individual PRS models. The pQTL weights were plotted in the y-axis for all genetic variants in the test gene region and color-coded with respect to $-\log_{10}$ (GWAS p-value). Test SNPs with GWAS p-value $<10^{-5}$ were colored.


Figure 3. PPI network and enrichment analyses results with 25 PWAS risk genes of AD dementia by STRING. Edges represent physical PPI, with different colors representing different sources of connection evidence. Node colors represent different enriched GO terms with FDR < 0.05 , 6 GO terms with most significant FDR q-value were colored.

Figure 4. Manhattan plot of TWAS results of AD dementia in DLPFC tissue. The $-\log_{10}(\text{q-value})$ were plotted on the y-axis, and $-\log_{10}(0.05)$ was plotted as the dashed horizontal line. Plotted TWAS q-values were obtained by the ACAT method, combining TWAS p-values obtained by TIGAR/DPR, PrediXcan/Elastic_Net, and FUSION/BestModel. Independent significant genes are labeled.


A. Brain tissue




B. CSF tissue




C. Plasma tissue




A. *APOE* (brain)











B. *BSG* (CSF)




C. *PROC* (plasma)









Connections:

-  **From curated databases**
-  **Experimentally determined**
-  **Gene neighborhood**
-  **Gene fusions**
-  **Gene co-occurrence**
-  **Textmining**
-  **Co-expression**
-  **Protein homology**



Enriched GO Terms

Biological Process	GO Term	FDR	Strength
 Immune response	GO:0006955	5.23E-07	0.81
 Glial cell proliferation	GO:0014009	0.0038	1.86
 Regulation of cell migration	GO:0030334	0.0105	0.75
 High-density lipoprotein particle clearance	GO:0034384	0.0131	2.27
 Regulation of cell-cell adhesion	GO:0022407	0.0131	0.91
 Positive regulation of protein metabolic process	GO:0051247	0.0322	0.59

